Letters Rosiglitazone saga

Authors’ reply

BMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d2567 (Published 21 April 2011) Cite this as: BMJ 2011;342:d2567
  1. Victor M Montori, professor of medicine,
  2. Nilay D Shah, assistant professor of health services research
  1. 1Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, MN 55902, USA
  1. montori.victor{at}mayo.edu

We agree that achieving glycaemic control is a tough task for clinicians and patients, and that high quality evidence and a strong regulatory framework are needed to guide care.1 2

Regarding the safety of rosiglitazone, the Nissen meta-analysis—despite its methodological shortcomings—yielded results that other more rigorous meta-analyses …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe